Cantor Fitzgerald Reiterates Overweight on Health Catalyst, Maintains $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on Health Catalyst (NASDAQ:HCAT) and maintained a price target of $16.
October 04, 2024 | 1:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on Health Catalyst, maintaining a $16 price target, indicating confidence in the company's potential.
The reiteration of an Overweight rating and maintenance of a $16 price target by a reputable analyst suggests positive sentiment and potential upside for Health Catalyst's stock. This could lead to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100